Results 111 to 120 of about 5,286 (232)

Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells

, 2005
Bruton's tyrosine kinase (BTK) deficiency results in a differentiation block at the pre-B cell stage. Likewise, acute lymphoblastic leukemia cells are typically arrested at early stages of B cell development.
Rowley, J. D., Hofmann, Wolf-Karsten, Liedtke, S., Soh, B. N. B., Rowley, J., Feldhahn, Niklas, Jumaa, Hassan, Müschen, M., Wernet, Peter, Sprangers, M., Hanenberg, H., Soh, B., Wernet, P., Hanenberg, Helmut, Klein, F., Rio, P., Jumaa, H., Feldhahn, N., Hofmann, W.   +18 more
core   +1 more source

Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis

JCI Insight, 2020
Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum.
Johann E. Gudjonsson, Lam C. Tsoi, Feiyang Ma, Allison C. Billi, K.R. van Straalen, A.R.J.V. Vossen, H.H. van der Zee, Paul W. Harms, Rachael Wasikowski, Christine M. Yee, Syed M. Rizvi, Xianying Xing, Enze Xing, Olesya Plazyo, Chang Zeng, Matthew T. Patrick, Margaret M. Lowe, Richard E. Burney, Jeffrey H. Kozlow, Jill R. Cherry-Bukowiec, Yanyun Jiang, Joseph Kirma, Stephan Weidinger, Kelly C. Cushing, Michael D. Rosenblum, Celine Berthier, Amanda S. MacLeod, John J. Voorhees, Fei Wen, J. Michelle Kahlenberg, Emanual Maverakis, Robert L. Modlin, Errol P. Prens   +32 more
doaj   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia

eJHaem
Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman, Michael Choi, Thomas J. Kipps   +2 more
doaj   +1 more source

Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib

, 2018
Ibrutinib, as the first Bruton's tyrosine kinase (Btk) inhibitor, has been shown to have clinically significant activity in leukemias and lymphomas. However, the initially responsive tumors will develop resistance during the process of treatment in few ...
Linyi Liu, Hua Xiang, Xiangqian Wang, Bingyu Shi   +3 more
core   +1 more source

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

ImmunoTargets and Therapy, 2021
Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...
Arneson LC, Carroll KJ, Ruderman EM
doaj  

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

American Journal of Hematology, Volume 101, Issue 7, Page 1632-1649, July 2026.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan, Yang Liu, Heng‐Huan Lee, Wei Wang, Joseph McIntosh, Yijing Li, Jovanny Vargas, Yue Fei, Sairah Ahmed, Lukas M. Simon, Michael Wang   +10 more
wiley   +1 more source

Image_4_Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.JPEG

, 2018
Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and ...
Sara Roman-Garcia (5724011), Rudi W. Hendriks (392253), Yolanda R. Carrasco (443116), Sara V. Merino-Cortes (5724014), Sofia R. Gardeta (5724017), Marjolein J. W. de Bruijn (519862)   +5 more
core   +1 more source

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

Therapeutic Advances in Neurological Disorders
Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Laura Airas, Robert A. Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J. Williams, Bernd C. Kieseier, Heinz Wiendl   +8 more
doaj   +1 more source

Profound Sinoatrial Arrest Associated with Ibrutinib

Case Reports in Oncological Medicine, 2017
Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia.
Kanupriya Mathur, Aditya Saini, Kenneth A. Ellenbogen, Richard K. Shepard   +3 more
doaj   +1 more source